TECX - Kapitalisasi marang volume dodolan Tectonic Therapeutic Inc.

Tandha merek Tectonic Therapeutic, Inc. (TECX)

The current P/S ratio helps assess the valuation of Tectonic Therapeutic, Inc. (TECX) through the lens of ESG standards and laboratory bioethics. Environmental sustainability is supported by closed-loop water systems at the plants to minimize the carbon footprint. However, FDA risks and a potential liquidity shortage create uncertainty. The mark characterizes this parameter, correlating market capitalization with the business's actual revenue.

TECX Multiplikator P/S Tectonic Therapeutic Inc. (04.07.2022 - 16.11.2026)

Rincian metrik lan analitis perusahaan Tectonic Therapeutic, Inc. (TECX)

- rega saham lan konsensus proyeksi valuasi:
Analisis fundamental perusahaan:Tectonic (TECX)
Produk merek Tectonic

When constructing a long-term portfolio, fundamental screening requires an analysis of the ratio of a business's market value to its annual turnover. This coefficient measures the premium investors are willing to pay per unit of revenue, which is critically important for Tectonic Therapeutic, Inc. (TECX) in the context of penetrating the complex protein target market, reflecting the valuation dynamics of the company's potential through its current P/S ratio.

Perusahaan pesaing

HLN (Haleon) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Kenvue Inc KVUE|Verona Pharma Corp - Rasio rega marang pendapatan|MENS: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Rasio rega marang pendapatan|Perrigo Company PLC - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan alvotech.com|Multiplikator P/S Liquidia Technologies|Rasio rega marang pendapatan Galapagos Genomics (GLPG)|ANIP: Rasio rega marang dodolan|Multiplikator P/S MNKD (MannKind Corp)|Koefisien rega marang pendapatan Amphastar (AMPH)|PCRX: Kapitalisasi marang pendapatan|SPRY - Multiplikator P/S|Theravance Biopharma, Inc. (TBPH) - Rasio rega marang pendapatan|AQST (Aquestive Therapeutics) - Rasio rega marang pendapatan|SCPH (scpharmaceuticals.com) - Multiplikator P/S|Multiplikator P/S Tonix Pharma|Kapitalisasi marang pendapatan SXTC (SXT Pharmaceuticals)|EPRX: Rasio rega marang dodolan|BioHarvest Sciences - Kapitalisasi marang pendapatan|EXOZ: Rasio kapitalisasi marang pendapatan|ORMP - Rasio rega marang pendapatan|ENTX: Rasio rega marang pendapatan|HYFT: Multiplikator P/S|Kapitalisasi marang pendapatan ABVC BioPharma Inc|CPIX (Cumberland Corp) - Multiplikator P/S|Multiplikator P/S quantumbiopharma.com|Multiplikator P/S FGEN|Kapitalisasi marang pendapatan Telomir Pharmaceuticals, Inc. TELO|Multiplikator P/S RANI (Rani Therapeutics)|SNYR (Synergy CHC Corp) - Rasio rega marang dodolan|RLYB: Kapitalisasi marang pendapatan|lexariabioscience.com (LEXX) - Kapitalisasi marang pendapatan|Pulmatrix Inc (PULM) - Rasio rega marang pendapatan|PTHL: Kapitalisasi marang volume dodolan|APM (Aptorum Group Ltd) - Multiplikator P/S|Lyra Therapeutics Inc (LYRA) - Koefisien rega marang pendapatan|Multiplikator P/S IBO|Kapitalisasi marang volume dodolan TNFA|cbdMD, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan PRFX|Altamira Therapeutics Ltd. - Multiplikator P/S|LIPO: Rasio rega marang pendapatan|OPTN: Multiplikator P/S|Rasio rega marang dodolan PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - Multiplikator P/S|PTPI (Petros Pharmaceuticals Inc) - Kapitalisasi marang volume dodolan|Multiplikator P/S QLI|SLRN - Rega marang dodolan|Multiplikator P/S TFFP (TFF Pharmaceuticals, Inc)